Understand your portfolio's true risk exposure. Beta and sensitivity analysis to reveal whether your holdings are properly positioned for your risk tolerance. Position appropriately based on your market outlook. Apollo Hospitals Enterprise has posted a 36% year-on-year increase in consolidated net profit for the fourth quarter of fiscal year 2026, reaching ₹529 crore. Revenue rose 18% to ₹6,605 crore, while the company’s board recommended a final dividend of ₹10 per share, reflecting sustained operational momentum.
Live News
Apollo Hospitals Reports 36% Jump in Q4 Net Profit to ₹529 Crore, Announces ₹10 Final Dividend{随机描述}- Net profit surge: Net profit rose 36% YoY to ₹529 crore in Q4 FY26, supported by higher revenue and operational efficiencies.
- Revenue growth: Total revenue increased 18% to ₹6,605 crore, driven by solid demand in both hospital and pharmacy segments.
- EBITDA expansion: EBITDA reached ₹1,011 crore, up 31.5% YoY, suggesting margin improvement amid rising input costs.
- Dividend announcement: Board recommended a final dividend of ₹10 per share for FY26, reflecting confidence in cash flow generation.
- Sector context: The results come amid a broader recovery in India’s healthcare sector, where occupancy rates and treatment volumes have been trending upward. Apollo’s performance may signal continued strength in demand for tertiary care services.
- Operational drivers: Factors such as higher average revenue per bed, increased surgical case mix, and expanded pharmacy network likely contributed to the top-line growth. The company also benefited from its integrated healthcare model, spanning hospitals, diagnostics, and digital platforms.
Apollo Hospitals Reports 36% Jump in Q4 Net Profit to ₹529 Crore, Announces ₹10 Final Dividend{随机描述}{随机描述}Apollo Hospitals Reports 36% Jump in Q4 Net Profit to ₹529 Crore, Announces ₹10 Final Dividend{随机描述}
Key Highlights
Apollo Hospitals Reports 36% Jump in Q4 Net Profit to ₹529 Crore, Announces ₹10 Final Dividend{随机描述}Apollo Hospitals Enterprise Ltd. announced its financial results for the fourth quarter and full fiscal year 2026, delivering robust growth across key metrics. The healthcare major’s consolidated net profit for the January–March 2026 quarter came in at ₹529 crore, a 36% improvement compared to the same period a year earlier. Revenue from operations climbed 18% year-on-year to ₹6,605 crore, driven by higher occupancy, increased average revenue per occupied bed, and continued expansion of its hospital and pharmacy networks.
Earnings before interest, taxes, depreciation, and amortization (EBITDA) grew by 31.5% year-on-year to ₹1,011 crore, indicating strong operating leverage. The EBITDA margin also improved, reflecting cost-control measures and a favorable patient mix.
In a separate filing, the company’s board recommended a final dividend of ₹10 per equity share (face value of ₹5 each) for the financial year ended March 31, 2026, subject to shareholder approval at the upcoming annual general meeting. The record date for the dividend has been set for a later date.
Apollo Hospitals operates one of India’s largest hospital chains, along with pharmacy, diagnostic, and health insurance businesses. Management attributed the performance to higher inpatient volumes, increased surgical procedures, and better realisation across segments. The company also noted that its digital health initiatives and Apollo 24/7 platform continued to gain traction.
Apollo Hospitals Reports 36% Jump in Q4 Net Profit to ₹529 Crore, Announces ₹10 Final Dividend{随机描述}{随机描述}Apollo Hospitals Reports 36% Jump in Q4 Net Profit to ₹529 Crore, Announces ₹10 Final Dividend{随机描述}
Expert Insights
Apollo Hospitals Reports 36% Jump in Q4 Net Profit to ₹529 Crore, Announces ₹10 Final Dividend{随机描述}The latest quarterly figures from Apollo Hospitals underscore the resilience of India’s organised healthcare providers, particularly in urban and metro markets. While the 36% net profit growth is notable, market participants are expected to focus on sustainability of margins, especially given ongoing cost pressures in the healthcare supply chain.
Analysts tracking the sector note that Apollo’s performance could be seen as a bellwether for the broader hospital industry, which has been benefiting from a post-pandemic normalization of elective procedures and a rise in lifestyle-related ailments. The company’s ability to grow revenue by 18% while expanding EBITDA by over 31% suggests that operating leverage is working in its favour, though this may be tempered by investments in new facilities and technology.
From a dividend perspective, the ₹10 per share payout aligns with the company’s historical dividend policy and signals management’s confidence in near-term cash flows. For long-term investors, the focus may shift toward how Apollo navigates regulatory changes, competition from regional chains, and the scalability of its digital health platform.
The hospital sector in India continues to attract attention as healthcare expenditure rises domestically. However, any downside could come from potential pricing caps on procedures or insurance reimbursement changes. Overall, Apollo’s Q4 results provide a data point that may reinforce positive sentiment toward the healthcare segment, but individual investment decisions should be based on a broader assessment of the company’s growth trajectory and valuation multiples.
Apollo Hospitals Reports 36% Jump in Q4 Net Profit to ₹529 Crore, Announces ₹10 Final Dividend{随机描述}{随机描述}Apollo Hospitals Reports 36% Jump in Q4 Net Profit to ₹529 Crore, Announces ₹10 Final Dividend{随机描述}
